Upregulation of erythropoietin receptor in human prostate carcinoma and high-grade prostatic intraepithelial neoplasia.

Abstract:

:The aim of the present study was to investigate the differential expression of erythropoietin receptor (EPOR) in prostate carcinoma (PCa), high-grade prostatic intraepithelial neoplasia (PIN), prostatic hyperplasia (BPH) lesions and normal prostatic tissues by immunohistochemistry; and to test the hypothesis that upregulation of EPOR is a specific event for prostate carcinogenesis. An immunohistochemical analysis of EPOR was performed on 30 PCa, 50 BPH with/without inflammation lesions and 30 normal prostatic tissue samples. EPOR staining was quantitated and classified into normal expression and overexpression. Totally 16 high-grade PIN lesions were found in this study. Overexpression of EPOR was shown only in PCa and high-grade PIN. Statistical analysis demonstrated that higher median EPOR staining score of PCa and high-grade PIN in comparison with BPH (P < 0.05) and higher median EPOR staining score of PCa compared with high-grade PIN (P < 0.05). Our data demonstrate that upregulation of EPOR is not uncommon for PCa and upregulated EPOR in high-grade PIN suggests upregulation of EPOR is an early event for prostate carcinogenesis. The role of upregulated EPOR and possibly enhanced EPOR signaling in prostate carcinogenesis warrants further studying.

authors

Zhou T,Xu C,He M,Sun Y

doi

10.1038/sj.pcan.4500995

subject

Has Abstract

pub_date

2008-01-01 00:00:00

pages

143-7

issue

2

eissn

1365-7852

issn

1476-5608

pii

4500995

journal_volume

11

pub_type

杂志文章
  • Insulin-like Growth Factor (IGF) Network and Prostate Pathologies.

    abstract::The Insulin-like Growth Factor (IGF) network in prostate tissue represents a key element in normal and tumour growth. It can provide us with new markers for prognosis or diagnosis and targets for treatment of prostate diseases. This short review introduces the IGF network in general and in the prostate gland, summaris...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500295

    authors: Tatoud R

    更新日期:1999-03-01 00:00:00

  • Patient-reported quality of life progression in men with prostate cancer following primary cryotherapy, cyberknife, or active holistic surveillance.

    abstract:BACKGROUND:Technological advancements have led to the success of minimally invasive treatment modalities for prostate cancer such as CyberKnife and Cryotherapy. Here, we investigate patient-reported urinary function, bowel habits, and sexual function in patients following CyberKnife (CK) or Cryotherapy treatment, and c...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-017-0004-y

    authors: Werneburg GT,Kongnyuy M,Halpern DM,Salcedo JM,Kosinski KE,Haas JA,Schiff JT,Corcoran AT,Katz AE

    更新日期:2018-09-01 00:00:00

  • Potential of intermittent hormone therapy for M+ and M0 prostate cancer patients.

    abstract::Increasingly animal and clinical studies suggest that intermittent therapy may improve the duration of hormone dependence in patients with prostate cancer. However there remains uncertainty as to optimal duration of treatment and level of prostate-specific antigen (PSA) before treatment is restarted. The aim of this s...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500483

    authors: Oliver RT,Farrugia D,Ansell W,Williams G,Chinegwundoh F

    更新日期:2000-12-01 00:00:00

  • A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.

    abstract:BACKGROUND:Intermittent androgen suppression (IAS) is an increasingly popular treatment option for castrate-sensitive prostate cancer. On the basis of previous data with anti-angiogenic strategies, we hypothesized that pan-inhibition of the vascular endothelial growth factor receptor using pazopanib during the IAS off ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/pcan.2011.49

    authors: Ward JE,Karrison T,Chatta G,Hussain M,Shevrin D,Szmulewitz RZ,O'Donnell PH,Stadler WM,Posadas EM

    更新日期:2012-03-01 00:00:00

  • The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.

    abstract:BACKGROUND:Several randomized controlled trials assessed the outcomes of patients treated with neoadjuvant hormonal therapy (NHT) before radical prostatectomy (RP). The majority of them included mainly low and intermediate risk prostate cancer (PCa) without specifically assessing PCa-related death (PCRD). Thus, there i...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2017.29

    authors: Tosco L,Laenen A,Briganti A,Gontero P,Karnes RJ,Albersen M,Bastian PJ,Chlosta P,Claessens F,Chun FK,Everaerts W,Gratzke C,Graefen M,Kneitz B,Marchioro G,Salas RS,Tombal B,Van den Broeck T,Moris L,Battaglia A,van d

    更新日期:2017-12-01 00:00:00

  • Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy.

    abstract:BACKGROUND:Intermittent androgen deprivation (IAD) for prostate cancer was studied with the objective of reducing the side effects of treatment and potentially delaying the development of hormone resistance. There also appears to be a quality of life benefit during off-treatment intervals owing to the recovery of serum...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/pcan.2012.12

    authors: Tunn UW,Canepa G,Kochanowsky A,Kienle E

    更新日期:2012-09-01 00:00:00

  • Fatigue in hormone-naïve prostate cancer patients treated with radical prostatectomy or definitive radiotherapy.

    abstract::Chronic fatigue (CF) is a distressing symptom that follows cancer treatment; however, it has rarely been studied in hormone-naïve prostate cancer survivors after radical prostatectomy (RP) or definitive radiotherapy (RAD). We investigated CF in prostate cancer survivors after RP or RAD as monotherapy and explored asso...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2009.61

    authors: Kyrdalen AE,Dahl AA,Hernes E,Cvancarova M,Fosså SD

    更新日期:2010-06-01 00:00:00

  • Prevalence of prostatic intra-epithelial neoplasia (PIN) in biopsies from hospital practice and pilot screening: clinical implications.

    abstract::As high grade PIN is commonly associated with concomitant cancer, current literature recommends re-biopsy of patients with high grade PIN. This paper describes the prevalence of high grade prostatic intra-epithelial neoplasia (PIN) from three independent clinical settings, reported by a single pathologist (MCP). High ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500210

    authors: Feneley MR,Green JS,Young MP,Bose P,Kirby RS,Peeling WB,Parkinson MC

    更新日期:1997-12-01 00:00:00

  • BPH in the next millennium:a glimpse to the future.

    abstract::Benign prostatic hyperplasia (BPH) is a highly prevalent, age-related disease. As the world population continues to grow and life expectancy increases, the population of men suffering from BPH will expand. A greater emphasis will be placed on quality of life. The BPH patient of the future will also have greater expect...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500370

    authors: Gómez-Sancha F

    更新日期:1999-12-01 00:00:00

  • Frequency of impalpable prostate adenocarcinoma and precancerous conditions in Greek male population: an autopsy study.

    abstract::A series of 212 prostate specimens of men dead between August 2002-August 2004, have been sectioned in consecutive autopsies and subjected to whole mount analysis in purpose to determine the epidemiology of impalpable prostate cancer in Greece. Impalpable prostate carcinomas were found in 40 cases (18.8%) most in the ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500847

    authors: Stamatiou K,Alevizos A,Perimeni D,Sofras F,Agapitos E

    更新日期:2006-01-01 00:00:00

  • Gene delivery into prostate cancer cells by holmium laser application.

    abstract::New approaches to treat prostate cancer (PCA) are utilizing gene therapy and aim to correct the disease at the genetic level. Getting a gene efficiently into the target cell is the subject of much interest. We used a holmium laser for transfecting rat PCA cells with the reporter gene pEGFP. By FACS analysis and fluore...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500653

    authors: Sagi S,Knoll T,Trojan L,Schaaf A,Alken P,Michel MS

    更新日期:2003-01-01 00:00:00

  • Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review.

    abstract:BACKGROUND:Certain patients presenting with either low or very-low-risk prostate cancer (PCa) can represent a therapeutic dilemma for physicians. The oncologic outcomes of active surveillance (AS) for men with very-low-risk PCa are overall excellent. However, there are concerns about AS related to the potential for upg...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/pcan.2016.56

    authors: Gökce MI,Sundi D,Schaeffer E,Pettaway C

    更新日期:2017-06-01 00:00:00

  • Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective.

    abstract:BACKGROUND:Several randomized control trials (RCTs) have showed that adding either abiraterone acetate (AA) or docetaxel (D) to androgen-deprivation therapy (ADT) improves survival of metastatic castration-sensitive prostate cancer patients (mCSPC). Yet, the cost-effectiveness of these treatment options has not been fu...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-019-0161-2

    authors: Chiang CL,So TH,Lam TC,Choi HCW

    更新日期:2020-03-01 00:00:00

  • Combined analysis of two multicenter studies of finasteride 5 mg in the treatment of symptomatic benign prostatic hyperplasia.

    abstract::The purpose of this paper is to examine effects of finasteride 5 mg across different age groups in an ethnically diverse population of men with symptomatic benign prostatic hyperplasia (BPH) seen in community urology and primary care practices. Data were combined from two previous placebo-controlled randomised trials ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500202

    authors: Byrnes CA,Liss CL,Tenover JL,Lippert MC,Gillenwater JY

    更新日期:1997-09-01 00:00:00

  • Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.

    abstract:BACKGROUND:Patients with high-risk prostate cancer have an increased likelihood of experiencing a relapse following radical prostatectomy (RP). We previously conducted three neoadjuvant androgen-deprivation therapy (ADT) trials prior to RP in unfavorable intermediate and high-risk disease. METHODS:In this analysis, we...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-017-0009-6

    authors: McKay RR,Montgomery B,Xie W,Zhang Z,Bubley GJ,Lin DW,Preston MA,Trinh QD,Chang P,Wagner AA,Mostaghel EA,Kantoff PW,Nelson PS,Kibel AS,Taplin ME

    更新日期:2018-09-01 00:00:00

  • Invasion of bladder neck after radical prostatectomy: one definition for different outcomes.

    abstract::The aim of the study was to evaluate factors of progression after radical prostatectomy in patients with bladder neck invasion (BNI). From 1988 to 2006, 1395 patients underwent radical prostatectomy, 120 (8.6%) had microscopic BNI (pT4 N0, TNM 2002). Group 1 was defined as BNI alone, group 2 as BNI plus extracapsular ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4501009

    authors: Rodriguez-Covarrubias F,Larré S,Dahan M,De La Taille A,Allory Y,Yiou R,Vordos D,Hoznek A,Abbou CC,Salomon L

    更新日期:2008-01-01 00:00:00

  • Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist.

    abstract:BACKGROUND:Gonadotrophin releasing hormone (GnRH) agonists and antagonists reduce testosterone levels for the treatment of advanced and metastatic prostate cancer. Androgen deprivation therapy (ADT) is associated with increased risk of cardiovascular (CV) events and CV disease (CVD), especially in patients with preexis...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-020-0264-9

    authors: Margel D,Ber Y,Peer A,Shavit-Grievink L,Pinthus JH,Witberg G,Baniel J,Kedar D,Rosenbaum E

    更新日期:2020-07-31 00:00:00

  • Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.

    abstract::An increased molecular understanding of localized prostate cancer and the improved ability for molecular testing of pathologic tissue has led to the development of multiple clinical assays. Here we review the relevant molecular biology of localized prostate cancer, currently available tissue-based tests and describe w...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/pcan.2015.31

    authors: Ross AE,D'Amico AV,Freedland SJ

    更新日期:2016-03-01 00:00:00

  • Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells.

    abstract::Recently, studies have investigated the significance of the Wnt/β-catenin pathway in prostate cancer. The transcriptional activity of the androgen receptor (AR) is modulated by interaction with coregulators, one of which is β-catenin. Curcumin, a dietary yellow pigment of Curcuma longa, has emerged as having a chemopr...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2010.26

    authors: Choi HY,Lim JE,Hong JH

    更新日期:2010-12-01 00:00:00

  • Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia.

    abstract::In light of the growing interest in the concept of 'uroselectivity' and in the increased worldwide use of alpha-blockers for benign prostatic hyperplasia (BPH), this review evaluates the relative benefits of various alpha-blocking agents in the treatment of BPH. The pharmacological and physiological selectivity as wel...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500302

    authors: Lowe F

    更新日期:1999-05-01 00:00:00

  • Effects of soy phytoestrogens on the prostate.

    abstract::Worldwide disparities exist between geographic regions with regard to prostate cancer incidence and mortality. Countries in East Asia have lower rates of prostate cancer compared with Western countries such as Canada and the US. Some suggest that dietary differences between the two geographic regions, particularly the...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/sj.pcan.4500953

    authors: Goetzl MA,Van Veldhuizen PJ,Thrasher JB

    更新日期:2007-01-01 00:00:00

  • The anticancer potential of metformin on prostate cancer.

    abstract:BACKGROUND:Prostate cancer (PCa) is characterized as the most frequent type of cancer in males. Recent research has suggested patients who have diabetes mellitus taking metformin (MF) have a lower risk of PCa. MF has antineoplastic effects such as adenosine monophosphate-activated protein kinase (AMPK)-dependent and in...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/s41391-018-0085-2

    authors: Zaidi S,Gandhi J,Joshi G,Smith NL,Khan SA

    更新日期:2019-09-01 00:00:00

  • Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project.

    abstract:BACKGROUND:Several treatment options for clinically localized prostate cancer currently exist under the established guidelines. We aim to assess nationally representative trends in treatment over time and determine potential geographic variation using two large national claims registries. METHODS:Men with prostate can...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2015.3

    authors: Cary KC,Punnen S,Odisho AY,Litwin MS,Saigal CS,Cooperberg MR,NIDDK Urologic Diseases in America Project.

    更新日期:2015-06-01 00:00:00

  • A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer.

    abstract:BACKGROUND:Focal therapy is an emerging mini-invasive treatment modality for localized prostate cancer aimed to reduce the morbidity associated with radical therapy while maintaining optimal cancer control. We report the mid-term oncological and functional results of primary hemiablation high-intensity focused ultrasou...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 临床试验,杂志文章

    doi:10.1038/pcan.2015.55

    authors: van Velthoven R,Aoun F,Marcelis Q,Albisinni S,Zanaty M,Lemort M,Peltier A,Limani K

    更新日期:2016-03-01 00:00:00

  • End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer.

    abstract:BACKGROUND:In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS:Prostate cancer patients consecutively treated with definitive radiation at our institution by a single provi...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2016.67

    authors: Narang AK,Trieu J,Radwan N,Ram A,Robertson SP,He P,Gergis C,Griffith E,Singh H,DeWeese TA,Honig S,Annadanam A,Greco S,DeVille C,McNutt T,DeWeese TL,Song DY,Tran PT

    更新日期:2017-06-01 00:00:00

  • The role of candidate genetic polymorphisms in the etiology of prostate cancer.

    abstract::Prostate cancer appears to result from complex interactions among genetic, endocrine and environmental factors. Identification of risk factors for development and progression of prostate cancer is needed. This will allow researchers to design strategies to reduce the morbidity and mortality from this cancer and to ide...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500471

    authors: Neuhausen SL

    更新日期:2000-12-01 00:00:00

  • Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer.

    abstract:BACKGROUND:Heat shock protein 27 (Hsp-27) encoded by gene HSPB1 is a critical regulator of the behavioral phenotype of human prostate cancer (PCa) cells, enhanced expression being associated with highly aggressive disease and poor clinical outcome. In contrast, the protein is not expressed in PCas of low malignant pote...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2012.47

    authors: Vasiljević N,Ahmad AS,Beesley C,Thorat MA,Fisher G,Berney DM,Møller H,Yu Y,Lu YJ,Cuzick J,Foster CS,Lorincz AT

    更新日期:2013-03-01 00:00:00

  • Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer.

    abstract:OBJECTIVE:To determine the prognostic value of serum chromogranin-A (CGA) in a two-cohort study of men with metastatic castrate resistant prostate cancer (mCRPC) and to compare with circulating tumor cells (CTCs)-based prognosis. PATIENTS AND METHODS:A two-cohort-based evaluation for serum CGA for prognostication in C...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-018-0046-9

    authors: Giridhar KV,Sanhueza C,Hillman DW,Alkhateeb H,Carlson R,Tan W,Costello BA,Quevedo F,Pagliaro L,Kohli M

    更新日期:2018-09-01 00:00:00

  • A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo.

    abstract::Functional expression of voltage-gated sodium channel alpha-subunits (VGSCalphas), specifically Nav1.7, is associated with strong metastatic potential in prostate cancer (CaP) in vitro. Furthermore, VGSC activity in vitro directly potentiates processes integral to metastasis. To investigate VGSCalpha expression in CaP...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500796

    authors: Diss JK,Stewart D,Pani F,Foster CS,Walker MM,Patel A,Djamgoz MB

    更新日期:2005-01-01 00:00:00

  • A prospective randomized comparison of extensive prostate biopsy to standard biopsy with assessment of diagnostic yield, biopsy pain and morbidity.

    abstract::In a prospective randomized study, we compare standard prostate biopsy to extensive biopsy utilizing intravenous conscious sedation (IVCS). Initial biopsy patients (n=197) were randomized to either standard biopsy using intrarectal lidocaine gel (6-12 biopsies, mean 10.1) or extensive biopsy (24 biopsies) using IVCS. ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1038/sj.pcan.4500713

    authors: Sur RL,Borboroglu PG,Roberts JL,Amling CL

    更新日期:2004-01-01 00:00:00